Latest Manufacturing And Distribution News

AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.

Centuria Industrial REIT has released its FY25 Property Compendium, detailing a $3.89 billion portfolio of 87 industrial assets across Australia, highlighting strong occupancy and long lease terms.

ClearVue Technologies has announced a major leadership overhaul alongside strategic partnerships and market expansion, highlighted by a solar façade trial in Hong Kong demonstrating a payback period as low as 2.6 years.

HITIQ Ltd has launched its PROTEQT smart mouthguard for grassroots sports, secured a five-year exclusive global partnership with Shock Doctor, and raised $1.9 million to fund manufacturing and market growth.

Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.

Capral Limited has agreed to acquire Perth-based aluminium systems distributor Comsupply Ltd, aiming to strengthen its foothold in Western Australia’s building systems market.

EVE Health Group has placed its first commercial purchase order for Dyspro™, a cannabinoid-based pharmaceutical targeting painful menstruation, signaling a key step toward market entry. The product is set for manufacturing and distribution within weeks, tapping into a rapidly growing global women’s health market.

Fletcher Building unveiled a comprehensive strategic review and FY25 outlook at its Investor Day, highlighting a focus on manufacturing and distribution alongside significant restructuring costs. The company targets a leaner operation with disciplined capital management and a net debt goal of NZD 400m to 900m.

RLF AgTech has resolved a legal dispute over a consultancy agreement, clearing the way for renewed focus on expanding its crop nutrition business domestically and internationally.

EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.